Annovis Bio Inc. (NYSE: ANVS), a clinical-stage company focused on developing treatments for neurodegenerative diseases such as Alzheimer’s and Parkinson’s, has successfully secured an 18-month compliance extension from the New York Stock Exchange (NYSE). This extension, effective from March 26, 2025, allows the company additional time to meet the NYSE's minimum market capitalization and stockholders’ equity requirements. The announcement underscores the NYSE's confidence in Annovis Bio's compliance plan and its commitment to maintaining listing standards.
The compliance extension ensures that Annovis Bio's shares will continue to be listed and traded on the NYSE, provided the company adheres to the milestones set forth in its compliance plan and meets all other listing criteria. Importantly, this development does not affect the company's operational activities, ongoing business initiatives, or its obligations to file reports with the Securities and Exchange Commission (SEC).
Annovis Bio's work in targeting multiple neurotoxic proteins to restore brain function represents a significant advancement in the treatment of neurodegenerative diseases. The company's innovative approach could potentially improve the quality of life for millions of patients worldwide. The NYSE's decision to grant an 18-month compliance window highlights the importance of Annovis Bio's research and development efforts in addressing some of the most challenging medical conditions of our time.
For further details on Annovis Bio's compliance plan and its implications for investors and the healthcare industry, visit https://ibn.fm/D9Yzt.
